Marinomed Biotech AG Seeks Court-Approved Restructuring Amid Financial Strains

Marinomed Biotech AG, based in Korneuburg, Austria, has announced its intent to apply for court restructuring proceedings without self-administration to secure financial stability. This move follows the breakdown of negotiations with Unither Pharmaceuticals, which failed to make earn-out payments crucial for Marinomed's previously court-approved restructuring plan of November 2024.

The company's decision aims to formulate a new restructuring plan necessary due to the risk of insolvency faced after these financial setbacks. Key to this strategy will be the utilization of legal mechanisms available against Unither regarding the sale of Marinomed's Carragelose business unit and the Marinosolv platform assets.